BridgeBio Board Member Fred Hassan Granted 15,000 Shares in Long-term Incentive Plan

Rhea-AI Filing Summary

BridgeBio Pharma Director Fred Hassan received new equity compensation grants on June 20, 2025, consisting of:

• 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 25,889 shares
• 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035

Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Hassan's continued service as a director. The awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing was signed on June 24, 2025, within the required reporting window.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hassan Fred

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,425	$0.00	--
Grant/Award	Common Stock	6,589	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,425 shares (Direct); Common Stock — 25,889 shares (Direct)

Footnotes (1)

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hassan Fred

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A(1)		6,589	A	$0(2)	25,889	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$41.73	06/20/2025		A		8,425		(3)	06/19/2035	Common Stock	8,425	$0	8,425	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Fred Hassan	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BBIO restricted stock units (RSUs) did Fred Hassan receive on June 20, 2025?

Fred Hassan received 6,589 restricted stock units (RSUs) on June 20, 2025, as part of BridgeBio's 2021 Amended and Restated Stock Option and Incentive Plan.

What is the vesting schedule for BBIO's RSUs granted to Fred Hassan in June 2025?

The RSUs will vest over three years, with one-third vesting each year after June 20, 2025. The RSUs will be fully vested on June 20, 2028, subject to Hassan's continued service on BridgeBio's board of directors.

What stock options did BBIO director Fred Hassan receive in June 2025?

Fred Hassan received stock options to purchase 8,425 shares of BBIO common stock at an exercise price of $41.73 per share. The options expire on June 19, 2035.

How many shares of BBIO does Fred Hassan own after the June 2025 transactions?

Following the reported transactions, Fred Hassan directly owns 25,889 shares of BBIO common stock, plus 8,425 stock options and 6,589 unvested RSUs.

What is Fred Hassan's role at BBIO according to the Form 4?

According to the Form 4 filing, Fred Hassan serves as a Director on BridgeBio Pharma's (BBIO) board of directors.